在IgA脏病中Sparsentan:一个简单的语言摘要的PROTECT研究的出版
Brad H Rovin1, Radko Komers2, Chris Scroggins3
1Ohio State University Wexner Medical Center, Columbus, OH, USA.
Therapeutic advances in rare disease
|July 22, 2025
概括
与伊尔贝沙坦相比,斯帕森坦显著减少了IgA脏病患者的蛋白尿症. 这一发现支持其用于高风险个体,可能减缓脏疾病的进展.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 临床药理学 临床药理学
- 免疫学 免疫学 免疫学
背景情况:
- 免疫球蛋白A (IgA) 病是一种进展性病.
- 高风险患者面临功能恶化.
- 目前的治疗方法旨在减少蛋白尿和减缓疾病的进展.
研究的目的:
- 评估sparsentan在IgA脏病中的疗效和安全性.
- 为了比较sparsentan与irbesartan在降低蛋白尿和保持功能方面.
- 在2年治疗期间报告PROTECT研究的进一步结果.
主要方法:
- 一项临床试验 (PROTECT研究) 涉及IgA脏病患者.
- 治疗臂包括斯帕森坦和伊尔贝沙坦 (最大剂量).
- 关键的结果措施是减少蛋白尿和改变估计的淋巴球过率 (eGFR).
主要成果:
- 在9个月后,与伊尔贝沙坦相比,Sparsentan显示蛋白尿的减少更大.
- 大约2年的进一步结果显示,斯帕森坦在降低蛋白尿和减缓eGFR下降方面继续带来好处.
- 该研究还描述了这两种治疗方法的副作用概况.
结论:
- 斯帕森坦是一种有效的治疗方法,用于降低IgA脏病的蛋白尿症.
- 斯帕森坦在高危患者中显示出减缓病进展的潜力.
- 这些发现有助于在多个地区在2024年批准sparsentan.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
830
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
830
Renal Drug Clearance: Overview
339
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
339
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
511
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
511
Renal Drug Excretion: Overview
284
As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
284
Dipeptidyl Peptidase 4 Inhibitors
262
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
262
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
891
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
891


